Drugs / AGS-v PLUS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04009824 | Jul 2019 → Mar 2020 | vector-borne disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGS-v PLUS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04009824 ↗ |
| Modality | Vaccine | “AGS-v PLUS vaccine” NCT04009824 ↗ |
| Route | Subcutaneous | “Administered by subcutaneous injection” NCT04009824 ↗ |